Dianthus Therapeutics Inc

Research Dianthus Therapeutics Inc (DNTH) on Bullrun: market cap USD 5.23B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDNTH
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 5.23B
• Financial periodFY2025
• RevenueUSD 2.04M
• Revenue growth-67.3%
• Net income-USD 162.34M

Valuation Snapshot

latest market cap is USD 5.23B.

About Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein;

Frequently asked questions

What is Dianthus Therapeutics Inc's market cap?

Dianthus Therapeutics Inc's market capitalization is USD 5.23B.

What does Dianthus Therapeutics Inc do?

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.